FeesSafety
Pluang+

Genelux reports Q3 2026 results, advances Olvi-Vec trials in ovarian and lung cancer with key data expected in 2H26.

Company Fundamentals
16 Nov 2026, 23:14 WIB
GlobeNewsWire
View Source
Bullish
Genelux reports Q3 2026 results, advances Olvi-Vec trials in ovarian and lung cancer with key data expected in 2H26.

Genelux Corporation announced its Q3 2026 financial results and progress on its Olvi-Vec immunotherapy trials targeting platinum-resistant ovarian cancer and lung cancers. The company expects topline data from its Phase 3 ovarian cancer trial in the second half of 2026 and continues dose-escalation studies in small cell and non-small cell lung cancer. Recent case reports show promising responses in lung cancer, supporting Olvi-Vec's potential to resensitize tumors to platinum chemotherapy. Genelux holds $15.5 million in pro forma cash to fund operations into early 2027 as it advances clinical and commercial development.

Genelux Corporation's Q3 2026 update comes as the health sector on Pluang saw 31 of 150 stocks rise and 118 fall. For readers following this sector, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: NUWE (Nuwellis Inc) traded at USD 4.53 with a 7.55% decline, ACB (Aurora Cannabis Inc) at USD 4.60 with a 6.88% drop and 100% sell order activity, and HRTX (Heron Therapeutics Inc) at USD 0.29 down 6.57% with balanced buy/sell orders and a typical hold time of 40 days.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App